Hester Pharmaceuticals Limited

Regd. Off.: Village: Merda-Adraj, Ta: Kadi, Dist: Mehsana, Gujarat - 382 721 UNAUDITED FINANCIAL RESULTS FOR THE PERIOD ENDED 31st DECEMBER, 2006

		1		Rs.In Lacs		
Sr.No.	Particulars	Quarter I		Nine Month's Ended on		Year Ended
		Unaudited		Unaudited		Audited
		31.12.2006		31.12.2006		31.03.2006
1	Manufacturing Sales	528.73	584.93	1400.05	1464.30	1965.45
	Trading Sales	1.67	7.42	185.80	38.50	48.25
	Net Income from Sales	530.40	592.35	1585.85	1502.80	2013.70
2	Other Income	1.78	0.14	7.45	1.58	3.01
3	Total Income	532.18	592.49	1593.30	1504.38	2016.71
4	Total Expenses	320.37	374.68	942.34	900.65	1120.45
	(a) (Increase)/decrease in Stock in trade	18.91	-97.41	-29.10	-147.81	-70.26
	(b) Trading Purchase	19.25	3.76	153.93	26.11	26.11
	(c) Consumption of Raw Material	101.76	141.40	254.35	372.92	452.56
	(d) Manufacturing Expenses	39.60	74.80	155.12	193.10	269.06
	(e) Staff Cost	52.85	40.69	138.93	114.77	151.64
	(f) Selling, General & Admn.Expenses	88.00	211.44	269.11	341.56	291.34
5	Interest	14.76	7.56	39.27	19.08	25.73
6	Depreciation.	9.54	8.98	28.17	26.52	35.38
7	Profit Before Extra Ordinary Item	187.51	201.27	583.52	558.13	835.15
8	Extra Ordinary Item	0.00	0.00	0.00	0.00	148.73
9	Profit before tax	187.51	201.27	583.52	558.13	686.42
10	Provision for taxation	63.75	82.29	202.05	205.29	243.01
	N . D . CI . CI	100 = /	110.00	201 1=	050.04	440.44
11	Net Profit after tax	123.76	118.98	381.47	352.84	443.41
		510.10	070.00	-10.10	070.00	.=
12	Paid-up equity share capital	519.12	370.80	519.12	370.80	370.80
	D					040.45
	Reserves & Surplus		-			943.65
	FDC (Da) (rack consultated)	2.20	2.27	7.05	10.00	40.44
	EPS (Rs.) (not annualised)	2.38	3.37	7.35	10.00	12.41
	Aggregate of New Dress-t					
	Aggregate of Non Promoters	2074404	2250/52	2074404	2250/52	00/44=0
	- Number of Share	2971424	2359650	2971424	2359650	2361150
	- % of Shareholding	57.24	63.64	57.24	63.64	66.94

- Note 1 The above results were reviewed by the audit committee and approved by the Board of Directors at their meeting held on 30.01.2007.

 The Statutory Auditors of the company has also carried out the Limited Review of the results.
 - 2 The expansion project will be on streamline before the end of current financial year.
 - 3 The proceeds of the Right issue (Rs.10.38 Cores) has been fully utilised towards the new expansion project.
 - **4** No investor complaint were pending at the beginning of the quarter. During quarter two complaint were received and were resolved. Pending complaint at the end of the quarter was nil.
 - 5 Segment wise reporting as defined in Accounting Standard (AS-17) is not applicable, since in the entire operation of the company relates to only one Segment i.e. Poultry Vaccines
 - 6 The provision for Taxation includes Dividend Tax, Current Tax and Fringe Benefit Tax as per Accounting Standard (AS-22)
 - 7 Earning Per Share has been calculated on the basis of Enhanced Paid up Capital for the quarter and nine months ended on 31.12.2006
 - 8 The figure have been regrouped wherever necessary

By Order of the Board

Place : AhmedabadRajiv GandhiDate : 30.01.2007CEO &Managing Director